These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29740160)

  • 1. New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.
    Cheung LC; Tickner J; Hughes AM; Skut P; Howlett M; Foley B; Oommen J; Wells JE; He B; Singh S; Chua GA; Ford J; Mullighan CG; Kotecha RS; Kees UR
    Leukemia; 2018 Nov; 32(11):2326-2338. PubMed ID: 29740160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.
    Frisch BJ; Ashton JM; Xing L; Becker MW; Jordan CT; Calvi LM
    Blood; 2012 Jan; 119(2):540-50. PubMed ID: 21957195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoclast activity modulates B-cell development in the bone marrow.
    Mansour A; Anginot A; Mancini SJ; Schiff C; Carle GF; Wakkach A; Blin-Wakkach C
    Cell Res; 2011 Jul; 21(7):1102-15. PubMed ID: 21321604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
    Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
    Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
    Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
    Kimachi K; Kajiya H; Nakayama S; Ikebe T; Okabe K
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):297-308. PubMed ID: 21225243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis.
    Hofkens W; Grevers LC; Walgreen B; de Vries TJ; Leenen PJ; Everts V; Storm G; van den Berg WB; van Lent PL
    J Control Release; 2011 Jun; 152(3):363-9. PubMed ID: 21396411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arctigenin suppresses receptor activator of nuclear factor κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages.
    Kim AR; Kim HS; Lee JM; Choi JH; Kim SN; Kim DK; Kim JH; Mun SH; Kim JW; Jeon HS; Kim YM; Choi WS
    Eur J Pharmacol; 2012 May; 682(1-3):29-36. PubMed ID: 22387094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
    Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anacardic acid inhibits RANKL-induced osteoclastogenesis
    Zhao K; Jia Y; Peng J; Pang C; Zhang T; Han W; Jiang J; Lu X; Zhu J; Qian Y
    FASEB J; 2019 Aug; 33(8):9100-9115. PubMed ID: 31050917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Bone Marrow Niche - The Tumor Microenvironment That Ensures Leukemia Progression.
    Cardoso BA
    Adv Exp Med Biol; 2020; 1219():259-293. PubMed ID: 32130704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-338-3p inhibits glucocorticoid-induced osteoclast formation through RANKL targeting.
    Zhang XH; Geng GL; Su B; Liang CP; Wang F; Bao JC
    Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
    Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
    J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
    Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
    Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting.
    Chiarini F; Lonetti A; Evangelisti C; Buontempo F; Orsini E; Evangelisti C; Cappellini A; Neri LM; McCubrey JA; Martelli AM
    Biochim Biophys Acta; 2016 Mar; 1863(3):449-463. PubMed ID: 26334291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyridone 6, a pan-Janus-activated kinase inhibitor, suppresses osteoclast formation and bone resorption through down-regulation of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL)-induced c-Fos and nuclear factor of activated T cells (NFAT) c1 expression.
    Kwak HB; Kim HS; Lee MS; Kim KJ; Choi EY; Choi MK; Kim JJ; Cho HJ; Kim JW; Bae JM; Kim YK; Park BH; Ha H; Chun CH; Oh J
    Biol Pharm Bull; 2009 Jan; 32(1):45-50. PubMed ID: 19122279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin Reduces Thyroid Cancer Tumor Growth in the Metastatic Niche of Bone by Inhibiting Osteoblastic RANKL Productions.
    Shin HS; Sun HJ; Whang YM; Park YJ; Park DJ; Cho SW
    Thyroid; 2021 May; 31(5):760-771. PubMed ID: 32791889
    [No Abstract]   [Full Text] [Related]  

  • 18. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
    Cai X; Xing J; Long CL; Peng Q; Humphrey MB
    J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosmarinic acid exerts an antiosteoporotic effect in the RANKL-induced mouse model of bone loss by promotion of osteoblastic differentiation and inhibition of osteoclastic differentiation.
    Lee JW; Asai M; Jeon SK; Iimura T; Yonezawa T; Cha BY; Woo JT; Yamaguchi A
    Mol Nutr Food Res; 2015 Mar; 59(3):386-400. PubMed ID: 25380345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures.
    Otsuka T; Kasai H; Yamaguchi K; Nishihara T
    J Dent; 2005 Oct; 33(9):749-55. PubMed ID: 16199283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.